Analysis
Embracing the science of value in health
Murray Krahn, Stirling Bryan, Karen Lee and Peter J. Neumann
CMAJ July 02, 2019 191 (26) E733-E736; DOI: https://doi.org/10.1503/cmaj.181606
Murray Krahn
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
MD MScStirling Bryan
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
PhDKaren Lee
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
MAPeter J. Neumann
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
ScDArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Embracing the science of value in health
Murray Krahn, Stirling Bryan, Karen Lee, Peter J. Neumann
CMAJ Jul 2019, 191 (26) E733-E736; DOI: 10.1503/cmaj.181606
Jump to section
Related Articles
Cited By...
- Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial
- Economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): study protocol
- Cost-effectiveness analysis should be mandatory in clinical-effectiveness research
Podcast